Description
Global HERG Screening Market Research Report—Forecast till 2027
Market Dynamics
Global hERG Screening Market is anticipated to record a substantial CAGR of 13.85% during the forecast period of 2020 to 2027, to surpass USD 3,304.58 Million by 2027. The expanding novel medication endorsements and the developing pervasiveness of heart illnesses are driving the worldwide hERG screening market. Notwithstanding, the significant expense of hERG screening items is required to hamper the development of this market during the gauge time frame. In any case, undiscovered business sectors are probably going to set a rewarding chance for the development of this market soon.
HERG screening is basically utilized for the medication disclosure measure. The expanding number of item dispatches is foreseen to support the interest for hERG screening in the coming years. As per the yearly report distributed by the Center for Drug Evaluation and Research (CDER), an expected 25 medications got novel medications endorsement for promoting in 2016, though 59 out of 2018. The expanding number of novel medications endorsements is required to help the medications disclosure measure that helps the hERG screening business sector to develop.
Market Segmentation
Global hERG Screening Market has been classified into Type into ion Channel and Application.
Based on type segment, the hERG screening market, has been segmented into gene KCNH2 and mutant KCNH2.
The global hERG screening market is classified, based on the ion channel, into voltage-gated ion channel, ligand-gated ion channel, and others.
The application segment is divided into antiarrhythmic drugs, antipsychotics, antibiotics, and others.
Regional Analysis
Geographically, the Global hERG Screening Market has been categorized into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to drive the largest market of the global hERG Screening market owing to largest market share of 37.3% of the hERG screening market in 2019. The regional market has been bifurcated into North America and Latin America. North America further divided into the US and Canada. The market growth of Americas is driven by the technological development and the high prevalence of cardiac disease in the region.
The European hERG screening market has been classified into Western Europe and Eastern Europe. The Western Europe hERG screening market has further been categorized into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The hERG screening market in Asia-Pacific has been divided into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The Middle East & Africa hERG screening market has been bifurcated into the Middle East and Africa.
Major Players
The Key Players in the Global hERG Screening Market include Charles River Laboratories, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Eurofins Scientific, Metrion biosciences, and Aurora Biomed. Some of the key strategies followed by players operating in the Global hERG screening market are FDA approvals, joint ventures, acquisitions, expansions, and collaborations.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Table of Contents
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS 14
1.2 MARKET ATTRACTIVENESS ANALYSIS 15
2 MARKET INTRODUCTION
2.1 DEFINITION 16
2.2 SCOPE OF THE STUDY 16
2.3 RESEARCH OBJECTIVE 16
2.4 MARKET STRUCTURE 16
2.5 ASSUMPTIONS & LIMITATIONS 17
3 RESEARCH METHODOLOGY
3.1 DATA MINING 18
3.2 SECONDARY RESEARCH 19
3.3 PRIMARY RESEARCH 20
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 21
3.5 FORECASTING TECHNIQUES 21
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
3.6.1 BOTTOM-UP APPROACH 23
3.6.2 TOP-DOWN APPROACH 23
3.7 DATA TRIANGULATION 24
3.8 VALIDATION 24
4 MARKET DYNAMICS
4.1 OVERVIEW 25
4.2 DRIVERS 26
4.2.1 INCREASING NOVEL DRUG APPROVALS 26
4.2.2 INCREASING PREVALENCE OF HEART DISEASES 26
4.3 RESTRAINT 27
4.3.1 HIGH COST OF HERG SCREENING PRODUCTS 27
4.4 OPPORTUNITY 28
4.4.1 UNTAPPED MARKETS 28
4.5 IMPACT OF CORONAVIRUS (COVID)-19 28
4.5.1 OVERVIEW 28
4.5.2 IMPACT ON PLAYERS 28
4.5.3 IMPACT ON CLINICAL TRIALS 28
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS 29
5.1.1 R&D AND DESIGNING 29
5.1.2 MANUFACTURING 30
5.1.3 DISTRIBUTION 30
5.1.4 MARKETING & SALES 30
5.1.5 POST-SALES MONITORING 30
5.2 PORTER’S FIVE FORCES MODEL 30
5.2.1 BARGAINING POWER OF SUPPLIERS 31
5.2.2 BARGAINING POWER OF BUYERS 31
5.2.3 THREAT OF NEW ENTRANTS 32
5.2.4 THREAT OF SUBSTITUTES 32
5.2.5 RIVALRY 32
5.3 TECHNOLOGICAL TRENDS IN GLOBAL HERG SCREENING MARKET 32
5.3.1 INCREASING TREND OF OUTSOURCING HERG SERVICES 32
5.3.2 ADVENT OF PATCH CLAMP ASSAY 33
5.3.3 STRATEGIC INITIATIVES BY PLAYERS IN THE MARKET 33
5.4 CUSTOMER NEED ANALYSIS 33
5.4.1 OVERVIEW 33
5.4.2 CLINICAL TRIAL FOR HERG SCREENING 33
5.4.3 CAUSE AND EFFECT ANALYSIS 34
6 GLOBAL HERG SCREENING MARKET, BY TYPE
6.1 OVERVIEW 35
6.2 GENE KCNH2 36
6.3 MUTANT KCNH2 36
7 GLOBAL HERG SCREENING MARKET, BY ION CHANNEL
7.1 OVERVIEW 37
7.2 VOLTAGE-GATED ION CHANNEL 39
7.3 LIGAND-GATED ION CHANNEL 39
7.4 OTHERS 40
8 GLOBAL HERG SCREENING MARKET, BY APPLICATION
8.1 OVERVIEW 41
8.2 ANTIARRHYTHMIC 43
8.3 ANTIPSYCHOTIC 43
8.4 ANTIBIOTIC 43
8.5 OTHERS 44
9 GLOBAL HERG SCREENING MARKET, BY REGION
9.1 OVERVIEW 45
9.2 AMERICAS 47
9.2.1 NORTH AMERICA 49
9.2.1.1 US 51
9.2.1.2 CANADA 52
9.2.2 LATIN AMERICA 53
9.3 EUROPE 54
9.3.1 WESTERN EUROPE 56
9.3.1.1 GERMANY 58
9.3.1.2 FRANCE 59
9.3.1.3 UK 60
9.3.1.4 ITALY 61
9.3.1.5 SPAIN 62
9.3.1.6 REST OF WESTERN EUROPE 63
9.3.2 EASTERN EUROPE 64
9.4 ASIA-PACIFIC 65
9.4.1 CHINA 67
9.4.2 JAPAN 68
9.4.3 INDIA 69
9.4.4 AUSTRALIA 70
9.4.5 SOUTH KOREA 71
9.4.6 REST OF ASIA-PACIFIC 72
9.5 MIDDLE EAST & AFRICA 73
9.5.1 MIDDLE EAST 75
9.5.2 AFRICA 76
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 77
10.2 MARKET RANKING ANALYSIS 77
10.3 COMPETITIVE BENCHMARKING 78
10.4 KEY DEVELOPMENTS AND GROWTH STRATEGIES 79
10.4.1 PARTNERSHIP 79
10.4.2 ACQUISITIONS 80
10.4.3 COLLABORATION 80
10.5 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 81
10.5.1 SALES & OPERATING PROFIT MARGIN 81
10.5.2 R&D EXPENDITURE 81
11 COMPANY PROFILES
11.1 THERMO FISHER SCIENTIFIC INC. 82
11.1.1 COMPANY OVERVIEW 82
11.1.2 FINANCIAL OVERVIEW 82
11.1.3 PRODUCTS/SERVICES OFFERED 83
11.1.4 KEY DEVELOPMENTS 83
11.1.5 SWOT ANALYSIS 83
11.1.6 KEY STRATEGIES 83
11.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 84
11.2.1 COMPANY OVERVIEW 84
11.2.2 FINANCIAL OVERVIEW 84
11.2.3 PRODUCTS/SERVICES OFFERED 85
11.2.4 KEY DEVELOPMENTS 85
11.2.5 SWOT ANALYSIS 86
11.2.6 KEY STRATEGIES 86
11.3 MERCK KGAA 87
11.3.1 COMPANY OVERVIEW 87
11.3.2 FINANCIAL OVERVIEW 87
11.3.3 PRODUCTS/SERVICES OFFERED 88
11.3.4 KEY DEVELOPMENTS 88
11.3.5 SWOT ANALYSIS 88
11.3.6 KEY STRATEGIES 88
11.4 EUROFINS DISCOVERX CORPORATION 89
11.4.1 COMPANY OVERVIEW 89
11.4.2 FINANCIAL OVERVIEW 89
11.4.3 PRODUCTS/SERVICES OFFERED 90
11.4.4 KEY DEVELOPMENTS 90
11.4.5 SWOT ANALYSIS 90
11.4.6 KEY STRATEGIES 91
11.5 ABCAM PLC. 92
11.5.1 COMPANY OVERVIEW 92
11.5.2 FINANCIAL OVERVIEW 92
11.5.3 PRODUCTS/SERVICES OFFERED 93
11.5.4 KEY DEVELOPMENTS 93
11.5.5 SWOT ANALYSIS 94
11.5.6 KEY STRATEGIES 94
11.6 CYPROTEX LIMITED 95
11.6.1 COMPANY OVERVIEW 95
11.6.2 FINANCIAL OVERVIEW 95
11.6.3 PRODUCTS/SERVICES OFFERED 95
11.6.4 KEY DEVELOPMENTS 95
11.6.5 SWOT ANALYSIS 96
11.6.6 KEY STRATEGIES 96
11.7 B‘SYS GMBH 97
11.7.1 COMPANY OVERVIEW 97
11.7.2 FINANCIAL OVERVIEW 97
11.7.3 PRODUCTS/SERVICES OFFERED 97
11.7.4 KEY DEVELOPMENTS 97
11.7.5 SWOT ANALYSIS 98
11.7.6 KEY STRATEGIES 98
11.8 CREATIVE BIOARRAY 99
11.8.1 COMPANY OVERVIEW 99
11.8.2 FINANCIAL OVERVIEW 99
11.8.3 PRODUCTS/SERVICES OFFERED 99
11.8.4 KEY DEVELOPMENTS 99
11.8.5 SWOT ANALYSIS 100
11.8.6 KEY STRATEGIES 100
11.9 METRION BIOSCIENCES LTD 101
11.9.1 COMPANY OVERVIEW 101
11.9.2 FINANCIAL OVERVIEW 101
11.9.3 PRODUCTS/SERVICES OFFERED 101
11.9.4 KEY DEVELOPMENTS 101
11.9.5 SWOT ANALYSIS 102
11.9.6 KEY STRATEGIES 102
11.10 AURORA BIOMED INC. 103
11.10.1 COMPANY OVERVIEW 103
11.10.2 FINANCIAL OVERVIEW 103
11.10.3 PRODUCTS/SERVICES OFFERED 103
11.10.4 KEY DEVELOPMENTS 103
11.10.5 SWOT ANALYSIS 104
11.10.6 KEY STRATEGIES 104
12 APPENDIX
12.1 REFERENCES 105
12.2 RELATED REPORTS 105
Reviews
There are no reviews yet.